The Therapeutic Use of Plasma from Covid-19 Convalescent Patients. (June 2021)

• Record Type: Journal Article
• Authors: Duque-Rodríguez, Jorge; Ishida-Gutiérrez, Cecilia; Espino-Solis, Gerardo Pavel
• Is Part Of: Plasmatology. Volume 15(2021)
• Publication Date: 2021-06
• Subjects: Convalescent plasma -- COVID-19 -- SARS-CoV-2 -- immune response -- antibodies; Blood plasma -- Periodicals; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 612.116
• DOI: 10.1177/26348535211018669
• Languages: English
• ISSNs: 2634-8535

Abstract

The outbreak of coronavirus disease (COVID-19) requires multidisciplinary teamwork to explore new methodological designs with the aim of approaching treatment strategies on different fronts. In principle, the rationale for the use of convalescent plasma is consistent from both an efficacy and safety point of view. Although there are still few completed randomized trials, the latest published results regarding efficacy are inconclusive. Immediate studies should target convalescent plasma preparations with a high titer of anti–SARS-CoV-2 antibodies and given early in the disease course. Regarding safety, its use with minimum risk factors or side effects is well documented. However, comparative research studies that involve the determination of antibody titers to support efficacy are required. Moreover, regulatory agencies and national blood systems should take a positive position via evaluation, supervisory, and control systems to maintain a blood-tissue store that meets the needs of the community and its hospitals.